论文部分内容阅读
[目的]探讨紫杉醇联合顺铂同步放化疗治疗术后食管癌的临床疗效。[方法]2000年10月～2007年10月,52例根治术后的Ⅱ～Ⅲ期食管癌患者均接受紫杉醇联合顺铂化疗同步放疗,放疗剂量:50Gy/25F,5周。[结果]28例(54%)患者发生了Ⅲ/Ⅳ级放化疗毒副反应,主要为白细胞下降/中性粒细胞减少、血小板减少和放射性食管炎。中位生存时间为37.2个月,1、3年生存率分别为82.19%、47.13%。2年局控率、无远处转移生存率和无进展生存率分别为60.01%、71.38%和42.01%。[结论]同步放化疗治疗Ⅱ～Ⅲ期术后食管癌患者可行,毒副反应可耐受。
[Objective] To investigate the clinical efficacy of paclitaxel combined with cisplatin in concurrent esophagectomy for the treatment of postoperative esophageal cancer. [Methods] From October 2000 to October 2007, 52 patients with stage Ⅱ ~ Ⅲ esophageal cancer after radical operation received concurrent chemoradiotherapy with paclitaxel combined with cisplatin. The dose of radiotherapy was 50Gy / 25F for 5 weeks. [Results] Grade Ⅲ / Ⅳ radiotherapy and chemotherapy toxicity occurred in 28 patients (54%), mainly leukopenia / neutropenia, thrombocytopenia and radiation esophagitis. The median survival time was 37.2 months, and the 1-year and 3-year survival rates were 82.19% and 47.13% respectively. 2-year local control rate, without distant metastasis and progression-free survival rates were 60.01%, 71.38% and 42.01%. [Conclusions] Concurrent chemoradiotherapy is feasible for patients with stage Ⅱ ~ Ⅲ postoperative esophageal cancer, and the side effects can be tolerated.